CN1221662C - 含有辅助分子配体基因的新表达载体和它们在免疫调节和治疗恶性肿瘤和自身免疫疾病中的应用 - Google Patents

含有辅助分子配体基因的新表达载体和它们在免疫调节和治疗恶性肿瘤和自身免疫疾病中的应用 Download PDF

Info

Publication number
CN1221662C
CN1221662C CNB971816743A CN97181674A CN1221662C CN 1221662 C CN1221662 C CN 1221662C CN B971816743 A CNB971816743 A CN B971816743A CN 97181674 A CN97181674 A CN 97181674A CN 1221662 C CN1221662 C CN 1221662C
Authority
CN
China
Prior art keywords
cells
ligand
gene
accessory molecule
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB971816743A
Other languages
English (en)
Chinese (zh)
Other versions
CN1246892A (zh
Inventor
托马斯·J·基普斯
桑贾伊·夏吗
马克·坎特维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
Original Assignee
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley filed Critical University of California Berkeley
Publication of CN1246892A publication Critical patent/CN1246892A/zh
Application granted granted Critical
Publication of CN1221662C publication Critical patent/CN1221662C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CNB971816743A 1996-12-09 1997-12-08 含有辅助分子配体基因的新表达载体和它们在免疫调节和治疗恶性肿瘤和自身免疫疾病中的应用 Expired - Fee Related CN1221662C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3214596P 1996-12-09 1996-12-09
US60/032,145 1996-12-09
US08/982,272 1997-12-01
US08/982,272 US7070771B1 (en) 1996-12-09 1997-12-01 Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells

Publications (2)

Publication Number Publication Date
CN1246892A CN1246892A (zh) 2000-03-08
CN1221662C true CN1221662C (zh) 2005-10-05

Family

ID=26708033

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB971816743A Expired - Fee Related CN1221662C (zh) 1996-12-09 1997-12-08 含有辅助分子配体基因的新表达载体和它们在免疫调节和治疗恶性肿瘤和自身免疫疾病中的应用

Country Status (16)

Country Link
US (3) US7070771B1 (https=)
EP (4) EP1806360A3 (https=)
JP (1) JP4015201B2 (https=)
CN (1) CN1221662C (https=)
AT (2) ATE420956T1 (https=)
AU (1) AU5795798A (https=)
BR (1) BR9714004A (https=)
CA (2) CA2707726C (https=)
DE (1) DE69739220D1 (https=)
DK (1) DK0948614T3 (https=)
ES (1) ES2321246T3 (https=)
IL (3) IL130247A0 (https=)
NO (2) NO327411B1 (https=)
NZ (1) NZ336092A (https=)
PT (1) PT948614E (https=)
WO (1) WO1998026061A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
JP2003508016A (ja) * 1999-04-16 2003-03-04 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
GB9917180D0 (en) * 1999-07-23 1999-09-22 Univ Sheffield Cell surface receptor
GB0025307D0 (en) * 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
EP1478390A2 (en) * 2002-02-25 2004-11-24 Isis Innovation Limited Novel complexes for inducing an immune response
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US20080044393A1 (en) * 2004-07-16 2008-02-21 White Robert L Retinal dystrophin transgene and methods of use thereof
WO2008109825A2 (en) * 2007-03-08 2008-09-12 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
US20100050276A1 (en) * 2008-08-22 2010-02-25 Brown University Transgenic non-human animal models of apoptosis-mediated conditions
WO2013083254A1 (en) 2011-12-09 2013-06-13 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
PL2908865T3 (pl) * 2012-10-17 2019-08-30 Vascular Biogenics Ltd. Adenowirus wykazujący ekspresję chimery Fas i jego zastosowanie w sposobach leczenia raka
WO2015148879A1 (en) * 2014-03-27 2015-10-01 The Regents Of The University Of Michigan Cancer immunotherapy compositions and methods
DK3143134T3 (da) 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
CN105567679B (zh) * 2014-10-10 2019-07-05 深圳市北科生物科技有限公司 可分泌型trail蛋白构建物和表达载体
US20180244750A1 (en) 2015-11-02 2018-08-30 Memgen, Llc Methods for treatment of cancer
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
WO2018191369A1 (en) 2017-04-12 2018-10-18 Memgen, Llc Methods of cd40 and toll like receptor immune activation
EP3749685A4 (en) 2018-02-09 2021-12-22 National University of Singapore ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
CN112725379B (zh) * 2021-01-27 2024-08-13 上海南方模式生物科技股份有限公司 人源化cd40基因改造动物模型的构建方法及应用
US11585330B1 (en) * 2021-09-29 2023-02-21 Halliburton Energy Services, Inc. Flow control for geothermal well

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750056T2 (de) 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
ATE87007T1 (de) 1987-05-29 1993-04-15 Sagami Chem Res Fusionsprotein, enthaltend lymphotoxin.
AU5940090A (en) 1989-08-16 1991-04-03 Cetus Oncology Corporation Compositions for the inhibition of protein hormone formation and uses thereof
US5519119A (en) 1990-09-21 1996-05-21 Ishihara Sangyo Kaisha Ltd. Muteins of TNF pharmaceutical compositions and a method of making
CA2055168A1 (en) 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
ES2198025T3 (es) 1991-10-25 2004-01-16 Immunex Corporation Anticuerpos contra cd40-l.
ATE242322T1 (de) 1992-03-30 2003-06-15 Immunex Corp Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
SK376492A3 (en) 1992-04-02 1995-06-07 Hoffmann La Roche Tnf - muteins and method of their production
ATE311895T1 (de) 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
AU5098493A (en) 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
WO1994004680A1 (en) 1992-08-21 1994-03-03 Schering Corporation Human interleukin-13
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
US5565321A (en) 1993-01-22 1996-10-15 Immunex Corporation Detection of mutations in a CD40 ligand gene
AU677995B2 (en) 1993-01-22 1997-05-15 Immunex Corporation Detection and treatment of mutations in a CD40 ligand gene
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5861310A (en) * 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
WO1995014487A1 (en) * 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide
ES2222463T3 (es) 1993-12-23 2005-02-01 Immunex Corporation Uso de anticuerpos monoclonales o ligandos oligomericos solubles en la fabricacion de un medicamento para la prevencion o tratamiento de trastornos neoplasicos.
ATE387458T1 (de) 1994-01-07 2008-03-15 Mochida Pharm Co Ltd Fas-antigenbindender ligand
ATE309267T1 (de) 1994-04-28 2005-11-15 Boehringer Ingelheim Pharma Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
US5606023A (en) 1994-05-24 1997-02-25 Thomas Jefferson University Mutant tumor necrosis factor proteins
US5759536A (en) 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
AU3111995A (en) 1994-07-22 1996-02-22 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5888764A (en) * 1995-01-20 1999-03-30 Uab Research Foundation Human fas gene promoter region
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6016832A (en) * 1997-04-16 2000-01-25 Woodward Governor Company Valve for controlling gas mass flow
ATE460482T1 (de) 1997-09-17 2010-03-15 Mochida Pharm Co Ltd Fas-liganden derivate
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof

Also Published As

Publication number Publication date
CA2707726A1 (en) 1998-06-18
NZ336092A (en) 2001-09-28
ATE547524T1 (de) 2012-03-15
JP2001505782A (ja) 2001-05-08
EP2145958B1 (en) 2012-02-29
EP0948614B1 (en) 2009-01-14
NO20074906L (no) 1999-08-09
EP0948614A2 (en) 1999-10-13
CA2274498A1 (en) 1998-06-18
US7070771B1 (en) 2006-07-04
NO327411B1 (no) 2009-06-22
US7906638B2 (en) 2011-03-15
AU5795798A (en) 1998-07-03
IL130247A0 (en) 2000-06-01
EP2145958A1 (en) 2010-01-20
JP4015201B2 (ja) 2007-11-28
CA2707726C (en) 2013-10-22
US7524944B2 (en) 2009-04-28
BR9714004A (pt) 2000-05-02
US20060183199A1 (en) 2006-08-17
EP1806360A3 (en) 2007-12-12
DE69739220D1 (de) 2009-03-05
ES2321246T3 (es) 2009-06-03
DK0948614T3 (da) 2009-05-11
EP1806360A2 (en) 2007-07-11
CA2274498C (en) 2010-06-29
IL178306A0 (en) 2007-02-11
WO1998026061A2 (en) 1998-06-18
NO331434B1 (no) 2011-12-27
NO992756D0 (no) 1999-06-07
IL130247A (en) 2008-03-20
ATE420956T1 (de) 2009-01-15
US20100267129A1 (en) 2010-10-21
WO1998026061A3 (en) 1998-11-19
EP2287309A1 (en) 2011-02-23
CN1246892A (zh) 2000-03-08
NO992756L (no) 1999-08-09
PT948614E (pt) 2009-04-20

Similar Documents

Publication Publication Date Title
CN1221662C (zh) 含有辅助分子配体基因的新表达载体和它们在免疫调节和治疗恶性肿瘤和自身免疫疾病中的应用
WO1998026061A9 (en) Expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease
CN100482283C (zh) 新型嵌合cd154
CN1308451C (zh) 肿瘤坏死因子相关配基
CN1539970A (zh) 嗜中性白细胞因子α
CN1428426A (zh) 编程性细胞死亡诱导分子ⅱ
CN1515672A (zh) 人类趋化因子β-8,趋化因子β-1和巨噬细胞炎性蛋白-4
CN1090326A (zh) 白细胞介素-10的哺乳动物受体
CN1194000A (zh) 增强保护性免疫应答的方法
CN1222536C (zh) 肝细胞癌的预防及治疗
CN1217024A (zh) 趋化因子α－2
CN1612890A (zh) 新型的嵌合tnf配体
CN1956997A (zh) 嵌合型可溶性超il－11和其应用
CN1784424A (zh) 编码人癌胚抗原的合成基因及其用途
CN1324404A (zh) 新型肿瘤抗原蛋白sart－3及其肿瘤抗原肽
CN1280307C (zh) 细胞毒性t淋巴细胞
CN1910284A (zh) 由HLA－A2402－限制的Ep－CAM－特异的CTL识别的表位/肽及其应用
AU781104B2 (en) Novel expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease
CN1157410C (zh) 人g蛋白偶联受体(hetgq23)
CN1244595C (zh) 一种肿瘤抑制蛋白及其应用
CN1234728C (zh) 新的人淋巴因子、其编码序列及用途
CN1181784A (zh) 编码淋巴细胞干扰素调节因子(lsirf）多肽的基因
MXPA99005326A (en) Novel expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease
CN1548455A (zh) 一种肿瘤抗原蛋白质和肿瘤抗原肽
CN1869064A (zh) 一种肿瘤抗原蛋白质和肿瘤抗原肽

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20051005

Termination date: 20141208

EXPY Termination of patent right or utility model